Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Infect Dis ; 215(12): 1862-1872, 2017 06 15.
Artigo em Inglês | MEDLINE | ID: mdl-28863472

RESUMO

A nurse who acquired Lassa virus infection in Togo in the spring of 2016 was repatriated to the United States for care at Emory University Hospital. Serial sampling from this patient permitted the characterization of several aspects of the innate and cellular immune responses to Lassa virus. Although most of the immune responses correlated with the kinetics of viremia resolution, the CD8 T-cell response was of surprisingly high magnitude and prolonged duration, implying prolonged presentation of viral antigens. Indeed, long after viremia resolution, there was persistent viral RNA detected in the semen of the patient, accompanied by epididymitis, suggesting the male reproductive tract as 1 site of antigen persistence. Consistent with the magnitude of acute T-cell responses, the patient ultimately developed long-term, polyfunctional memory T-cell responses to Lassa virus.


Assuntos
Anticorpos Antivirais/sangue , Linfócitos T CD8-Positivos/imunologia , Imunidade Celular , Febre Lassa/imunologia , Vírus Lassa/imunologia , Vírus Lassa/isolamento & purificação , Adulto , Amidas/uso terapêutico , Antígenos Virais/imunologia , Antivirais/uso terapêutico , Ensaio de Imunoadsorção Enzimática , Humanos , Switching de Imunoglobulina/genética , Febre Lassa/sangue , Ativação Linfocitária , Masculino , Pirazinas/uso terapêutico , Ribavirina/uso terapêutico , Viremia/sangue
2.
Clin Infect Dis ; 63(4): 460-7, 2016 08 15.
Artigo em Inglês | MEDLINE | ID: mdl-27353663

RESUMO

BACKGROUND: Ebola virus (EBOV) infection causes a severe and often fatal disease. Despite the fact that more than 30 000 individuals have acquired Ebola virus disease (EVD), the medical and scientific community still does not have a clear understanding of the mechanisms by which EBOV causes such severe disease. METHODS: In this study, 54 biomarkers in plasma samples serially collected from 7 patients with EVD were analyzed in an attempt to define the kinetics of inflammatory modulators. Two clinical disease groups were defined (moderate and severe) based on the need for clinical support. Biomarkers were evaluated for correlation with viremia and clinical disease in an effort to identify pathways that could be useful targets of therapeutic intervention. RESULTS: Patients with severe disease had higher viremia than those with moderate disease. Several biomarkers of immune activation and control were significantly elevated in patients with moderate disease. A series of pro-inflammatory cytokines and chemokines were significantly elevated in patients with severe disease. CONCLUSIONS: Biomarkers that were associated with severe EVD were proinflammatory and indicative of endothelial or coagulation cascade dysfunction, as has been seen historically in patients with fatal outcomes. In contrast, biomarkers that were associated with moderate EVD were suggestive of a strong interferon response and control of both innate and adaptive responses. Therefore, clinical interventions that modulate the phenotype and magnitude of immune activation may be beneficial in treating EVD.


Assuntos
Quimiocinas/sangue , Citocinas/sangue , Ebolavirus/imunologia , Doença pelo Vírus Ebola/imunologia , Imunidade Humoral , Adulto , Biomarcadores/sangue , Coagulação Sanguínea , Estudos de Coortes , Células Endoteliais/imunologia , Feminino , Doença pelo Vírus Ebola/fisiopatologia , Doença pelo Vírus Ebola/terapia , Humanos , Inflamação , Cinética , Masculino , Pessoa de Meia-Idade , Índice de Gravidade de Doença , Viremia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA